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Background: Subcutaneous immunotherapy with high dose grass pollen (typically microgram quantities) was first
described over 100 years ago. This treatment suppresses allergen-induced cutaneous late responses, with lesser effects
on early responses. We previously reported that repeated 2-weekly intradermal injections of grass pollen - containing
approximately 7 ng of major allergen Phl p 5 – led to a progressive suppression of the allergen-induced cutaneous
response, and that by the sixth injection, this was inhibited by over 90%. The purpose of this trial is to investigate the
clinical efficacy of intradermal desensitisation with low doses (i.e. nanogram quantities) of grass pollen allergen for
seasonal allergic rhinitis.
Methods/design: The Pollen Low dose Intradermal therapy Evaluation (PollenLITE) is a single centre double-blind
randomised parallel group controlled trial of the efficacy and safety of intradermal grass pollen injections plus standard
treatment, versus histamine injections plus standard treatment, in adults with moderate-severe grass pollen-induced
allergic rhinitis (‘summer hay fever’). A minimum of ninety adults with a history of moderate-severe persistent allergic
rhinitis during the UK grass pollen season will be randomised into two equal groups to receive 7 or 8 intradermal
injections of grass pollen extract (containing approximately 7 ng of major allergen Phl p 5) or histamine, before the
grass pollen season. In the summer, participants will score their symptoms, medication requirements, visual analogue
scores, and complete EuroQOL (EQ-5D-5 L) and mini Rhinoconjunctivitis Quality of Life Questionnaires. Global
assessments will also be recorded at the end of the pollen season. Blood samples will be collected from all participants
for mechanistic immune assays. Skin punch biopsies will also be collected in 40 participants selected at random from
intradermal injection sites after the grass pollen season for mechanistic assays. Finally, to investigate if the desensitising
effect of intradermal immunotherapy on cutaneous responses is long-lasting, all participants will be randomised to
receive a follow up intradermal injection after 3, 6 or 12 months with measurement of early and late response sizes.
Discussion: Randomisation began in February 2013 and the final participant will complete the trial protocol in
August 2014.
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Allergic rhinitis caused by grass pollen affects a quarter of
the UK population [1]. Of these, around 5 million people
suffer moderate-severe persistent symptoms that have an
impact on quality of life, including disturbed sleep, disrup-
tion of leisure activities and impairment of performance at
work/school [2]. Therefore, there is a substantial unmet
need for both therapy and prophylaxis of seasonal allergic
rhinitis. In the UK, subcutaneous and sublingual immuno-
therapy is indicated in patients with moderate-severe
symptoms who fail to respond to conventional medica-
tions [3]. Immunotherapy i.e. prophylactic inoculation
with grass pollen for treatment of season allergic rhinitis
was first described in 1911 [4]. The conventional approach
involves the regular subcutaneous administration of aller-
gen extracts at high doses (typically microgram quantities
of Group 5 grass pollen allergens) [3]. The most com-
monly used form of grass pollen immunotherapy is that
given by injections into the tissue beneath the skin (i.e.
subcutaneously) over a period of 2–3 years with increasing
amounts of allergen administered weekly for 12 to
15 weeks followed by monthly maintenance injections [3].
A body of evidence, including a Cochrane meta-analysis
[5], exists to support the clinical efficacy of high dose sub-
cutaneous immunotherapy. Grass pollen allergen may also
be administered at high dose as sublingual tablets or
drops, an approach further supported by Cochrane meta-
analysis [6]. Both subcutaneous and sublingual high dose
immunotherapy have limitations: the vaccine products are
expensive and the need for repeated administration in a
specialist clinic (subcutaneous immunotherapy) or daily at
home (sublingual immunotherapy) is associated with add-
itional expense and/or inconvenience.
‘Proof of concept’ has been established for a novel low
dose intradermal desensitisation protocol in subjects with
grass pollen-induced allergic rhinitis. A feature of an intra-
dermal allergen injection is the development of local
swelling within 6 hours, and persisting for 24–36 hours.
This ‘late response’ is characterised by infiltration of in-
flammatory cells, notably activated TH2 cells, eosinophils
and basophils. We showed that six two-weekly intrader-
mal injections of grass pollen containing only 7 ng of
major allergen Phl p 5 resulted in a >90% suppression in
the cutaneous late response measured after 24 hours in re-
sponse to these injections [7]. Although the injection siteswere alternated between left and right arms, this effect
was systemic since responses were also suppressed at a
distal site (the back). The magnitude of inhibition was
comparable to that seen with a conventional high dose
subcutaneous grass pollen vaccine [8] despite equating to
over 1000-fold less allergen over the same time period. A
grass pollen extract produced by the same manufacturer
and given as sublingual immunotherapy delivered 20'000-
fold more group 5 allergen over a 10 week period than was
given in this study, but was associated with lesser inhibition
of late responses, an approximate 40% reduction compared
to placebo [9]. We believe that these findings provide a
strong rationale for progressing to a clinical trial. The con-
cept of therapeutic intradermal allergen inoculation is not
without precedent. In 1926, Phillips, a physician working in
Arizona, published a preliminary account of his uncon-
trolled experiences with intradermal grass pollen immuno-
therapy in 29 patients [10], extended to 322 patients by
1933 [11], over 90% of whom obtained “satisfactory relief”.
However, no randomised controlled trial has yet addressed
the efficacy of intradermal low dose allergen injections.
High dose subcutaneous immunotherapy is associated
with induction of regulatory T cells (Tregs) [12-14],
probably through interaction of CD4+ T cells with pro-
tolerogenic dendritic cells (DC). These cells are anti-
inflammatory and also induce B cell production of
allergen-specific ‘blocking’ IgG antibodies. Low dose
intradermal allergen desensitisation is biologically plaus-
ible: for example, intradermal injection of radiotracers in
animal models results in 100-fold higher rates of drain-
age to regional lymph nodes than subcutaneous injection
[15], potentially leading to more efficient pulsing of
lymph node dendritic cells. Also, the dermis is itself an
immunologically active environment, rich in Langerhans
cells, dermal DC, and lymphatics [16,17]. In contrast,
conventional subcutaneous immunotherapy injections
target a compartment consisting mostly of connective
and adipose tissue but few DC. Irrespective of whether
intradermal antigen is processed by DC locally or within
draining lymph nodes, we speculate that the basis of the
low dose intradermal desensitisation effect is the highly
efficient targeting of pro-tolerogenic dendritic cell popu-
lations leading to induction of antigen-specific Tregs.
The rationale for the laboratory mechanistic studies
using skin biopsies and blood specimens is three-fold.
Slovick et al. Clinical and Translational Allergy 2013, 3:27 Page 3 of 14
http://www.ctajournal.com/content/3/1/27Firstly, there is a need to establish the effects of intra-
dermal immunotherapy on inflammatory cell responses
to allergen in tissue (particularly eosinophils, basophils,
mast cells and T cells). Suppression of the allergen-
induced late response in the skin and nose occurs in
parallel following conventional subcutaneous immuno-
therapy, and the underlying immunological changes
within these tissues are extremely similar, if not identi-
cal [18-25]. Secondly, we shall investigate if low dose
intradermal desensitisation is associated with a systemic
immunological effect. We will therefore measure serum
allergen-specific IgE and IgG responses and test the bio-
logical inhibitory activity of IgG antibodies with an in-
house validated assay of IgE-allergen complex binding
to B cells [26]. We shall also examine the effect of low
dose intradermal allergen treatment on peripheral blood
basophil activation in response to grass pollen stimula-
tion ex vivo. There is also a need for exploratory studies
to investigate underlying causative mechanisms. These
studies will take the form of analysis of T cells expanded
from skin biopsy explants in short term cultures. Fi-
nally, it is now established that both conventional high
dose subcutaneous and sublingual grass pollen im-
munotherapy exert long-term effects that persist after
treatment discontinuation [27,28]. Extended clinical tri-
als involving three successive years of treatment show
continued clinical improvement for several years after
withdrawal of treatment. To definitively assess such a
comparative effect on symptoms/medication use with
low dose intradermal immunotherapy would therefore
ideally require a prolonged five year trial. Therefore we
will perform exploratory studies to investigate the per-
sistence of the intradermal desensitisation effect. We
will do this by monitoring how suppression of the skin
late response induced by treatment persists over a
12 month follow up period. Therefore the participants
in the active and control groups (estimated n = 45 each)
will be further sub-randomised to one of three sub-
groups (estimated n = 15 each). After having completed
their main ‘treatment’ injections, each sub-group will
subsequently receive a single follow-up intradermal in-
jection with allergen with late response measurement
after 3, 6 or 12 months. For each time point the size of
late response in the group that originally received active
therapy will be compared with the group that originally
received the control intervention.Methods/design
We hypothesise that low dose intradermal grass pollen al-
lergen immunotherapy is an effective treatment for sea-
sonal allergic rhinitis (‘hay fever’), reducing symptoms and
rescue medication requirements, and improving quality of
life for hay fever sufferers.Primary objective
To determine if pre-seasonal low dose intradermal grass
pollen allergen immunotherapy (either 7 or 8 two-weekly
injections of 10 Biological Units (33.3 SQ-U)) reduces
symptoms and requirements for anti-allergic drugs in sea-
sonal allergic rhinitis during the 2013 grass pollen season
compared to the control intervention (histamine only).
Secondary objectives
To
1) Determine if this intervention is associated with
improvement in quality of life compared to the
control intervention, as assessed during the 2013
grass pollen season.
2) Evaluate if this is a safe and well-tolerated form of
treatment.
3) Investigate immunological mechanisms associated
with this form of treatment, by examining humoral
and cellular responses, both in peripheral blood and
in tissue.
4) Explore if the intradermal desensitisation effect is
long-lived i.e. persists following cessation of
intradermal injections.
Study design
PollenLITE is a single center (UK) double-blind ran-
domised parallel group controlled trial of the efficacy
and safety of 7 to 8 pre-seasonal intradermal injections
of Phleum pratense grass pollen extract (each con-
taining estimated 7 ng of major allergen Phl p 5) versus
histamine control (Figures 1 and 2). The study is based
at Guy’s Hospital, King’s College London. A minimum
of 90 participants will be recruited and randomised 1:1
to receive active or control injections before the 2013
grass pollen season, when the clinical outcome data
will be collected. All participants will also have access
to conventional pharmacotherapy for allergic rhinitis.
All participants will be consented in accordance with
the Declaration of Helsinki. The study has been ap-
proved by the London Harrow Research Ethics Com-
mittee (reference 12/LO/0941).
Primary endpoint
Combined symptom and medication score covering the
grass pollen season period of 13th May-end August 2013.
Secondary endpoints
1. Symptom score for each participant, covering the grass
pollen season period of 13th May-end August 2013.
2. Medication score for each participant, covering the
peak grass pollen season period of 13th May-end
August 2013.
Figure 1 Study design.
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Rhinoconjunctivitis Quality-of-Life Questionnaire
(32) and the EQ-5D-5L questionnaire, during the
peak grass pollen season.
4. A Visual Analogue Score for each participant,
covering the peak grass pollen season period (mid
May-end Aug 2013).
5. A global evaluation by each participant, at the end
of the 2013 grass pollen season, of symptoms and a
comparison with previous years.6. Number of primary care (i.e. general practitioner)
visits for hay fever during summer 2013.
7. Combined symptom and medication score during
the peak of the 2013 grass pollen season.
8. Number of medication free days covering the grass
pollen season period of 13th May-end August 2013.
9. Number of symptom free days covering the grass
pollen season period of 13th May-end August 2013.
10. Individual symptoms scores (AUC) for each organ:
nose, mouth, eyes and lungs.
Figure 2 Study schedule.
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used between 13th May-end August 2013.
12. Frequency of adverse events, including the
occurrence of systemic allergic reactions.
Secondary endpoints in mechanistic assays
1) Inflammatory cells (eosinophils, mast cells,
basophils, CD4+ T cells and Foxp3+ T cells) in skin
biopsies collected 24 hours after receiving an
intradermal diluent (negative control) and grass
pollen allergen injection in September 2013.
2) Numbers of CRTH2posCD203cposCD3negCD303neg
and CRTH2posCD63posCD3negCD303neg activated
peripheral blood basophils cells following in vitro
activation with grass pollen allergen (Visit 7).
3) Serum concentrations of Phleum pratense-specific
IgG, IgG1, IgG4 and IgE at Visit 1 and Visit 7.
These sera will also be tested for inhibitory activity
against allergen-IgE complex binding to B cells.
4) Gene expression profiles of CD4+ T cells derived
from skin biopsy explants in September 2013.
5) Cutaneous allergen-induced late response size
measured in December 2013 (i.e. approx. 3 months
after previous intradermal injection), March 2014
(6 months) or August 2014 (11–12 months).Definition of end of study
The duration of the trial is 2 years. The trial will end
when the last subject makes the last visit to determine
the late response following the final open label follow
up intradermal injection at the August 2014 time
point.
Subject selection and withdrawal
Inclusion criteria
1) Adults aged 18 to 65 years.
2) A clinical history of grass pollen-induced allergic
rhinoconjunctivitis for at least 2 years with peak
symptoms in May, June, or July.
3) A clinical history of moderate-severe persistent
rhinoconjunctivitis symptoms interfering with usual
daily activities or with sleep.
4) A clinical history of rhinoconjunctivitis that remains
troublesome despite treatment with either
antihistamines or nasal corticosteroids during the
grass pollen season.
5) Positive skin prick test response, defined as wheal
diameter greater than or equal to 3 mm,
to Phleum pratense.
6) Positive specific IgE, defined as greater than or equal
to IgE class 2, against Phleum pratense.
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an effective form of contraception for the duration
of intradermal injections.
8) The ability to give informed consent and comply
with study procedures.
Exclusion criteria
1) Pre-bronchodilator FEV1 less than 70% of predicted
value at screening visit.
2) A history of seasonal grass pollen-induced asthma
requiring regular treatment with salbutamol or
inhaled corticosteroids. Patients with mild seasonal
grass pollen-induced asthma may be included,
provided symptoms are satisfactorily controlled with
occasional salbutamol only.
3) A clinical history of symptomatic seasonal allergic
rhinitis and/or asthma due to tree pollen or weed
pollen near or overlapping the grass pollen season,
although patients with mild intermittent symptoms
requiring only occasional antihistamines may
be included.
4) A clinical history of symptomatic allergic rhinitis
and/or asthma caused by a perennial allergen to
which the participant is regularly exposed, although
patients with mild intermittent symptoms requiring
only occasional antihistamines may be included.
5) Emergency department visit or hospital admission
for asthma in the previous 12 months.
6) History of chronic obstructive pulmonary disease.
7) History of significant recurrent acute sinusitis,
defined as 2 episodes per year for the last 2 years, all
of which required antibiotic treatment.
8) History of chronic sinusitis, defined as a sinus
symptoms lasting greater than 12 weeks outside the
grass pollen season, that includes 2 or more major
factors or 1 major factor and 2 minor factors. Major
factors are defined as facial pain or pressure, nasal
obstruction or blockage, nasal discharge or
purulence or discolored postnasal discharge,
purulence in nasal cavity, or impaired or loss of
smell. Minor factors are defined as headache, fever,
halitosis, fatigue, dental pain, cough, and ear pain,
pressure, or fullness.
9) At randomisation, current symptoms of, or
treatment for, upper respiratory tract infection,
acute sinusitis, acute otitis media, or other relevant
infectious process; serous otitis media is not an
exclusion criterion. Participants may be re-evaluated
for eligibility after symptoms resolve.
10) Current smokers or a history of greater than or
equal to 5 pack years.
11) Previous treatment by immunotherapy with grass
pollen allergen within the previous 5 years.12) History of life-threatening anaphylaxis or
angioedema.
13) Ongoing systemic immunosuppressive treatment.
14) History of intolerance of grass pollen
immunotherapy, rescue medications or their
excipients.
15) For females of childbearing age a positive serum or
urine pregnancy test with sensitivity of less than
50 mIU/mL within 72 hours of first administration
of study therapy.
16) Lactating females.
17) The use of any investigational drug within 30 days
of the screening visit.
18) Ongoing treatment with leukotriene receptor
antagonists, beta-blockers, calcium channel blockers,
tricyclic antidepressants, monoamine oxidase
inhibitors or anti-IgE monoclonal antibody.
19) The presence of any medical condition that the
investigator deems incompatible with participation
in the trial.
20) Individuals with insufficient understanding of
the trial.
Recruitment
Participants for PollenLITE will be identified via a re-
cruitment campaign including advertisements in press,
online and on public transport. Potential participants
will be invited to visit the trial website (www.pollenlite.
co.uk) and answer 7 pre-screening questions before reg-
istering. Participants passing pre-screening on the trial
website will be contacted for further telephone screen-
ing, and if considered potentially suitable will be invited
to attend the Clinical Research Facility at Guy’s Hospital
for a formal screening visit. A Participant Information
Sheet will be provided to each person to read prior to
the screening visit. At the screening visit (Visit −1), there
will be an opportunity to ask questions of a staff mem-
ber trained in all trial procedures, as formally delegated
by the PI. Written informed consent will be obtained by
a physician prior to screening and any other study spe-
cific procedures taking place. The original signed con-
sent form will be retained in the Investigator Site File,
with a copy filed in the participant’ s hospital records,
and a further copy provided to the participant. Individ-
uals will be free to decline further participation without
giving reasons. The screening visit will comprise a full
medical and allergic history, skin prick testing to a panel
of common inhalant allergens, recording of concomitant
medications, limited physical examination, measurement
of vital signs, spirometry and collection of a venous
blood sample for total and Phleum pretense-specific IgE
levels and for storage for serum based mechanistic as-
says (baseline sample). For participants who either do
not meet the eligibility criteria at the screening visit or
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will be recorded where known. The history and test re-
sults of every potentially eligible participant will be
reviewed by the PI before an appointment is made for
Visit 1 (randomisation and first injection). To ensure
that a minimum of 90 participants is randomised, up to
100 screened participants will be booked for visit 1,
allowing for a 10% drop-out rate between screening and
randomisation. In the event that more than 90 eligible
participants attend for visit 1, all will be included in the
study and randomised up to a maximum of 100. All fe-
male participants of childbearing age will be required to
undergo a urine pregnancy test with sensitivity of less
than 50 mIU/mL within 72 hours of randomisation and
first administration of study therapy at Visit 1.
Trial medication
The active drug will be 10 Biological Units (BU) (33.3
SQ-U) of Phleum pratense soluble grass pollen extract
(Aquagen SQ Timothy, ALK Abello, Reading UK) con-
tained in a 20 microliter volume (i.e. 500 BU/ml (1666.7
SQ-U/ml)). Individual vials for each participant and
each visit will be pre-prepared and pre-labeled by Guy’s
Hospital Pharmacy under GMP conditions. In brief,
Aquagen SQ Timothy Grass Pollen extract will be
reconstituted in manufacturer-supplied diluent to the
maximum recommended concentration (30'000 BU/ml
(100'000 SQ-U/ml) i.e. 60-times final working strength;
shelf life 6 months at 2-8°C after reconstitution) and
0.15 ml aliquoted into glass study vials. At each visit for
intradermal injection the investigator will add 8.85 ml
of clinical grade 0.9% normal saline at ambient tem-
perature to the vial corresponding to that participant’s
visit to achieve a 60-fold dilution. Twenty microliters
will then be aspirated from this vial and administered
directly. The allergen requires dilution on the day of ad-
ministration as the recommended shelf life of Aquagen
SQ Timothy Grass Pollen extract at 500 BU/ml (1666.7
SQ-U/ml) is only 14 days. Control drug will be hista-
mine only, administered at a concentration of 100 mcg/
ml. To help preserve blinding, histamine concentrations
will be reduced to 30 mcg/ml for the 3rd and 4th injec-
tions, and 10 mcg/ml for 5, 6 and 7th injections. To
match the grass pollen extract dilution and preserve
blinding, histamine will also be aliquoted into study
vials at 60-times final working strength in 0.15 ml vol-
umes, for further dilution with 8.85 ml of clinical grade
0.9% normal saline immediately prior to injection. Ac-
tive and control study medications will appear identical.
Following manufacture, vials will be packed into indi-
vidual dispensing packs that will be dispensed by phar-
macy against a single study prescription for each study
participant, covering all visits. At randomisation, an
email will be sent from the randomisation system to thedispensing pharmacy. On receipt of a study prescription,
the pharmacist will refer to this email to select an appro-
priate pack of active or control medication. The pack
will then be fully blinded and dispensed. The blinded
dispensed packs will thereafter be stored in the Clinical
Research Facility in temperature monitored fridges in a
secure environment.
Dosing regimen
A series of 7 intradermal active or control injections will
be administered 2-weekly into the forearm between before
the 2013 grass pollen season. The first injection will be ad-
ministered between 18th February and 1st March 2013.
We will aim to administer the 7th injection between 13th
May and 24th May 2013. The injection site will again be
alternated between left and right arms at each visit. Intra-
dermal injections will be administered in a 20 micro-
liter volume using a 29 gauge insulin syringe (Becton
Dickinson Micro-FineTM). As a precaution against sys-
temic allergic reactions all subjects will be observed for
one hour after the first injection, and for 30 minutes
after subsequent injections, in a clinical area with full
resuscitation facilities.
Occasionally an injection may be administered too
deeply (into subcutaneous tissue) resulting in failure to
generate an immediate injection ‘bleb’ and subsequent
characteristic wheal. For this reason, the injection site
will be inspected in all subjects 15 minutes after each in-
jection to confirm successful intradermal injection. In
the absence of the typical wheal, the injection will be re-
peated at 1 cm from the original site.
In the event of acute illness (e.g. upper respiratory
tract infection) or other unforeseeable circumstance, ad-
ministration of active/control intervention may be post-
poned up to a maximum of 3 weeks since the previous
injection, at the discretion of the investigator. The study
team aim to perform over 90% of injections at 12–
16 day intervals, although in exceptional circumstances
the minimal interval permitted between injections may
be reduced to 7 days. Onset of symptoms associated
with the London grass pollen season generally falls be-
tween late May - early June. Therefore, if schedule ad-
justments result in a participant completing their 7
injections before 13th May 2013, the 7th injection will
be repeated 12–16 days later in late May.
Following these injections, clinical outcomes will be
measured during the summer of 2013. In September 2013
and either 3, 6 or 12 month later, all participants will also
receive intradermal injections with diluent (negative
control) or 10 BU (33.3 SQ-U) of grass pollen allergen. Al-
though the trial will not be unblinded at this stage, these
intradermal injections will be open label.
Most participants will not be taking antihistamines at
the time of intradermal injections since these will be
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all participants will be asked to avoid taking antihista-
mines for 5 days before receiving an intradermal injec-
tion so that the presence of a wheal can be confirmed.
Following an intradermal injection participants may take
an antihistamine to reduce the local itching and swelling.
If they wish to do so before leaving the clinical research
facility an antihistamine tablet will be provided. The ex-
ception will be visits 10 and 11, when cutaneous re-
sponse sizes will be measured and therefore participants
will be asked to refrain from taking an antihistamine.
Any oral steroids must be stopped for a minimum of
2 weeks before the intradermal injection in September
2013 since this may interfere with late response measure-
ments and skin biopsy studies. Participants will be asked to
refrain from alcohol consumption on the same day before
and for 2 hours after an intradermal injection.
Study medication accountability
Study drug accountability will be assessed and docu-
mented by Guy’s Hospital Pharmacy. Study vials that have
been reconstituted in saline for injection and used will be
stored separately at room temperature after use for return
to pharmacy for drug accountability to be assessed.
Concomitant medications
Rescue medications will be provided to participants before
and throughout the pollen season. These will include:
desloratadine (5 mg, up to 1 tablet daily), (olopatadine eye
drops, 1.0 mg/mL, up to 1 drop per eye twice daily), flu-
ticasone propionate nasal spray 50 mcg per spray, up to 2
sprays per nostril once daily), and prednisone (for use at
30 mg per day for up to 5 days). Participants will be asked
to use only these medications to treat their hay fever
symptoms on an as required basis. However, participants
who are not getting hay fever symptoms will be encour-
aged to try not to use these medications. Participants will
be asked to use only these medications. A short course of
prednisolone will be available if symptoms are particularly
severe. Participants will be instructed to contact a trial
physician prior to taking any prednisolone. The doctor will
then provide instructions on dose and duration of treat-
ment. Concurrent treatment with beta-blockers, calcium
channel blockers, tricyclic antidepressants, monoamine
oxidase inhibitors or anti-IgE monoclonal antibody will
not be permitted.
Randomisation
The King’s Clinical Trial Unit (KCTU) at King’s College
London will host a 24 hour web based randomisation sys-
tem. Participants will be randomised 1:1 to active and
comparator medications by the method of block random-
isation with randomly varying block sizes, stratified by the
size of skin test response to grass pollen at screening visit(the cut-off skin prick test size will be the median value of
all subjects to be randomised) and presence/absence of
rhinitis symptoms outside the grass pollen season. Study
medication will be blinded. To minimise bias through ac-
cidental unblinding as a result of common injection site
reactions in the active trial arm, the control intervention
will consist of a reducing dose of histamine, which will
produce similar clinical effects as the active medication.
All physicians, researchers, research nurses, outcome as-
sessors and patients will remain blinded to treatment allo-
cation until the primary analysis is completed. The trial
statistician will be sub-group unblind only. The KCTU
randomisation service provider and the manufacturing
pharmacy only will have access to the blinding informa-
tion for the study.
In August 2013, KCTU will randomly select participants
to be approached in rotation to undergo skin biopsies.
The first 40 participants who agree will then undergo bi-
opsy after giving additional procedure-specific informed
consent. Also in August 2013, KCTU will randomise all
participants for a second time to one of three groups
(3 months, 6 months or 12 months). These 3 groups will
then undergo repeat intradermal allergen injections at 3, 6
or 12 months, respectively, to assess if low dose intrader-
mal allergen immunotherapy is associated with prolonged
suppression skin responses.
Withdrawal of participants
The study therapy (active or control) will be discontinued
for any of the following reasons:
1. Inability or failure to attend for intervention within
3 weeks of previous administration.
2. Inability or failure to receive 7 or 8 injections within
the dates specified.
3. Two Grade 2 systemic reactions, or a single
systemic reaction of Grade 3 or above after
administration of study therapy. Systemic reactions
will be graded according to the World Allergy
Organization (WAO) criteria: Grade 1: symptoms of 1 organ system (cutaneous,
upper respiratory tract, conjunctival,
gastrointestinal, other);
 Grade 2: symptoms of more than 1 organ system
present or asthma symptoms/signs (cough,
wheezing, shortness of breath but < 40% drop in
peak expiratory flow [PEF] or FEV1).
 Grade 3: asthma symptoms/signs (with ≥ 40%
drop in PEF or FEV1), upper respiratory tract
(laryngeal, uvula, tongue) oedema with or
without stridor.
 Grade 4: respiratory failure or hypotension with
or without loss of consciousness.
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principal investigator or the medical monitor,
presents an unacceptable consequence or risk to
the participant.
5. An illness or infection that is not associated with the
condition under study and that requires treatment
not consistent with protocol requirements; or, if a
participant develops an intercurrent illness that in
the judgment of the principal investigator in any
way justifies discontinuation.
6. An inability or unwillingness to comply with the
study protocol, and the protocol deviations are
sufficient to jeopardise the participant’s well-being
or the integrity of the study.
7. Pregnancy occurs during study participation.
Participants have the right to withdraw from the study
at any time for any reason. The investigator also has the
right to withdraw patients from the study drug in the
event of inter-current illness, AEs, SAE’s, SUSAR’s, proto-
col violations, cure, administrative reasons or other rea-
sons. As an excessive rate of withdrawals could render the
study uninterpretable unnecessary withdrawal of patients
will be avoided where possible. Should a participant decide
to withdraw from the study, all efforts will be made to re-
port the reason for withdrawal as thoroughly as possible.
Should a participant withdraw from study drug only, ef-
forts will be made to continue to obtain follow-up data,
with the permission of the patient. A 10% allowance has
been included in the sample size to account for with-
drawal and participants will only be replaced if this occurs
prior to randomisation. The statistical analysis also incor-
porates a plan for dealing with missing data from symp-
tom and medication diary cards.
Assessment of efficacy
Primary efficacy parameters
The primary outcome measure will be daily symptoms
and medication use during the 2013 grass pollen season.
The scoring systems have been adapted from previous tri-
als of grass pollen immunotherapy [29]. Participants will
record symptom scores each day (reflecting the preceding
24 hours) in diary cards from mid-May through to the
end of August. The symptom score will be based on indi-
vidual symptoms in the nose (sneezing, blockage, and run-
ning), eyes (itching, redness, tears, and swelling), mouth
and throat (itching and dryness), and chest (breathless-
ness, cough, wheezing, and tightness), recorded on a scale
of 0 to 3 (with a score of 0 indicating no symptoms and 1,
2, and 3 indicating mild, moderate, and severe symptoms,
respectively). The maximum daily symptoms score will
therefore be 39. All possible rescue medications will be
provided to each participant approximately 2 weeks before
and throughout the pollen season. Participants will beasked to use medications to treat symptoms on an as re-
quired basis. Daily medication use will also be recorded in
diary cards by participants and a medication score calcu-
lated based on use according to need of the following
medications: desloratadine, 5 mg, up to 1 tablet daily (6
points per day); olopatadine eye drops, 1.0 mg/mL, up to
1 drop per eye twice daily (1.5 points per drop, up to 6
points per day); fluticasone nasal spray, 50 mcg per spray,
up to 2 sprays per nostril once daily (2 point per spray, up
to 8 points per day); and prednisone, 5 mg per tablet, up
to 6 tablets per day (2 points per tablet, up to 12 points
per day). All these medications will be provided to partici-
pants free of any charge. The maximum daily medication
score will therefore be 32. For each participant, both the
symptom score and the medication score will be individu-
ally expressed as area under curve (AUC) values for the
period corresponding to the grass pollen season (mid
May - August 2013). Since maximum scores for symp-
toms and medications are different in magnitude these
parameters will be normalised as recommended World
Allergy Organization guidelines [30]. Normalised AUC
scores will then be added together to generate a combined
symptom and medication score in accordance with World
Allergy Organization guidance on immunotherapy trials
[30]. Efficacy will then be assessed by comparison of this
combined score in active and control groups.
Secondary efficacy parameters
The following will be compared in active and control
groups:
1) Symptom scores (AUC) calculated as above.
2) Medication scores (AUC), calculated as above.
3) Rhinoconjunctivitis Quality of Life: mini Rhinitis
Quality of Life Scores (RQLQ) scores (overall score
and domain scores) will be recorded three times
during the pollen season (June 12, June 26 and July
10) and once after the season on 4 September
2013. These values will be compared in active and
control groups. The mini RQLQ covers five
dimensions of health including sleep, non-nose/eye
symptoms, practical problems, nasal symptoms,
eye symptoms.
4) Health related quality of life: This will be evaluated
using the EQ-5D-5L questionnaire three times
during the pollen season (June 12, June 26 and July
10) and once after the season on 4 September 2013.
5) Visual Analogue Scores (see Additional file 1). These
will be recorded every 2 weeks during the pollen
season and AUC values calculated.
6) Global evaluation scores (see Additional file 2).
7) The number of primary care (i.e. general
practitioner) visits for hay fever during
summer 2013.
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the peak* of the 2013 grass pollen season.
9) Number of medication free days covering the grass
pollen season period of 13th May-end August 2013
will be compared in active and control groups.
10) Number of symptom free days covering the grass
pollen season period of 13th May-end August 2013
will be compared in active and control groups.
11) Individual symptoms scores (AUC) for each organ:
nose, mouth, eyes and lungs.
12) Total number of days during which prednisolone
used between 13th May-end August 2013.
*The peak of grass pollen season will be defined as
starting on the first 3 consecutive days between 13 May
and 31 August 2013 when grass pollen counts in central
London are ≥ 30 grains/cm3, using counts supplied by the
UK Met Office. The end of the peak season will be defined
as the first of 3 consecutive days when grass pollen counts
are < 30 grains/cm3. In the event of 2 or more peaks dur-
ing the 2013 season, these individual peak periods will be
analysed separately.
The persistence of late response suppression will be
evaluated by randomising active and control subjects in
Aug 2013 into 3 groups. Each group will receive a follow-
up intradermal injection of 10 BU (33.3 SQ-U) of grass
pollen allergen, as well as a diluent control injection, at ei-
ther 3, 6 or 12 months. Reversal of late response suppres-
sion will be assessed at each time point by comparing
mean late response size in the active and control groups.
Procedures for assessing efficacy parameters
Primary efficacy parameters
All participants will be supplied with diary cards. They will
be asked to score symptoms and medication use for each
day. Participants will be asked to provide a copy of the first
diary card (corresponding to 13–30 May 2013) during the
first week of June by post, fax or email. Thereafter original
cards will be collected approximately monthly for tran-
scription to the eCRF. Participants will be contacted with
regular reminders to complete the cards. As a further pre-
caution against lost data, every participant will be indi-
vidually contacted by telephone, email or in person to
provide 24 hour dairy card data for 13th May, 1st July and
31st August 2013 to be used to assist in the statistical im-
putation of missing data in the event of incomplete data.
Secondary efficacy parameters
The Visual Analogue Scores will require completion every
2 weeks over the summer. Participants will be reminded
to complete these as above and these will be collected at
the same visits. Mini RQLQ and EQ-5D-5 L forms will be
completed three times during the pollen season (June 12,
June 26 and July 10) and once after the season on 4September 2013. These forms will be collected at visits 8,
9 and 10.
Safety
Specification, timing and recording of safety parameters
All adverse events and side effects will be recorded in
the electronic case report form (eCRF) throughout the
study regardless of their severity or relation to study
participation.
Systemic allergic reactions to grass pollen intradermal
injections are a theoretical possibility. As a precaution,
all participants in this trial will be observed after the
first intradermal injection for one hour, and if there is
no systemic reaction, for 30 minutes after subsequent
injections (since the dose of allergen given does not in-
crease at later visits). All injections will be given in a
clinical area with resuscitation facilities in the presence
of a physician. If a participant has a Grade 2 reaction
(see above) they may continue in the study but the ob-
servation period will be increased to 1 hour after each
subsequent injection. In the event of a further Grade 2
reaction, that participant will not be permitted to
continue in the study. In the event of a participant ex-
periencing a Grade 1 reaction, the clinical observation
period for that individual will also be maintained at
1 hour after subsequent injections. In the event of a sin-
gle Grade 3 or 4 reaction, that participant will not be
permitted to continue in the study.
Procedures for recording and reporting adverse events
These details are outlined in Additional file 3.
Adverse events that do not require reporting
These will include the following:
1) Symptoms due to aeroallergen exposure i.e. nasal
blockage, rhinorrhea, itching or sneezing; Itching,
watering redness or swelling of eyes; itching or
dryness of mouth/throat; breathless, cough, wheeze
and chest tightness.
2) Transient discomfort from intradermal injections.
3) Appearance of an itchy oedematous wheal with
surrounding erythema (early response) after
intradermal injection.
4) Appearance of swelling (oedema) within hours of
intradermal injection, that may persist for several
days (late response). These responses may be
associated with very mild local tenderness.
5) Temporary discomfort,, bleeding, bruising, swelling
at the needle site following venesection, and in rare
instances, infection. Some people may experience
lightheadedness, nausea, or fainting.
6) Mild localised itching arising from skin prick testing
during screening.
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The trial will be stopped in the event of five grade 3 reac-
tions or a single grade 4 reaction. In addition the trial may
be prematurely discontinued by the Sponsor, Chief Investi-
gator or Regulatory Authority on the basis of new safety
information or for other reasons given by the Data Moni-
toring & Ethics Committee/Trial Steering Committee
regulatory authority or ethics committee. The trial may
also be prematurely discontinued due to lack of recruit-
ment or upon advice from a Trial Steering Committee
who will advise on whether to continue or discontinue
the study and make a recommendation to the sponsor.
If the study is prematurely discontinued, participants
will be informed and no further participant data will
be collected.
Code breaking
24 hr Emergency Code Break and Medical Information
will be provided by Guy’s & St Thomas’ NHS Foundation
Trust Emergency Scientific Medical Services (eSMS). Each
randomised subject will be provided with a card detailing
code break telephone numbers and emergency contact de-
tails. Subjects will be requested to carry this card with
them at all times whilst participating in the trial.
Study data
Data handling
The Chief Investigator will act as custodian for the trial
data. The following guidelines will be strictly adhered
to:
 Patient data will be anonymised.
 All anonymised data will be stored on a password
protected computer.
 All trial data will be stored in line with the
Medicines for Human Use (Clinical Trials)
Amended Regulations 2006 and the Data
Protection Act and archived in line with the
Medicines for Human Use (Clinical Trials)
Amended Regulations 2006 as defined in the
King’s Health Partner’s Clinical Trials Office
Archiving SOP.
Data management
Data will be managed using the InferMed MACRO data-
base system. An electronic Case Report Form (eCRF)
will be created using the InferMed Macro system. This
system is regulatory compliant (GCP, 21CRF11, EC Clin-
ical Trial Directive). The eCRF will be created in collab-
oration with the trial statisticians and the CI and
maintained by the King’s Clinical Trials Unit. It will be
hosted on a dedicated secure server within KCL. Source
data will be entered by authorised staff onto the eCRF
with a full audit trail.Database passwords
Database access will be strictly restricted through pass-
words to the authorised research team. The CI or delegate
will request usernames and passwords from the KCTU. It
is a legal requirement that passwords to the eCRF are not
shared, and that only those authorised to access the sys-
tem are allowed to do so. If new staff members join the
study, a personalised username and password will be re-
quested via the CI or delegate.
Data handling & confidentiality/format of records
Data will be handled, computerised and stored in ac-
cordance with the Data Protection Act, 1998. Partici-
pants will be identified on the study database using a
unique code and initials. The investigator will maintain
accurate patient records/results detailing observations
on each patient enrolled.
Identifiable data
All participant contact information data will be stored
on spreadsheets within the recruiting NHS site, which
will have restricted access from password protected
computers. Accrual data uploaded to the UKCRN port-
folio database will be anonymised and collated by the CI
or delegate to the CLRN. No identifiable data will be en-
tered on the eCRF or transferred to the KCTU.
Main database
SAE data will be collected on paper SAE report forms and
faxed to the KHPCTO. Summary details of SAEs will be
transcribed to adverse event section of the eCRF. For all
other data collected, source data worksheets will be pre-
pared for each patient and data will be entered onto the
eCRF database. Source data worksheets will be reconciled
at the end of the trial with the patients NHS medical notes
in the recruiting center. During the trial, critical clinical
information will be written in the medical notes to ensure
informed medical decisions can be made in the absence of
the study team. Trial related clinical letters will be copied
to the medical notes during the trial. The Chief Investiga-
tor will provide an electronic signature for each patient
Case Record Form once all queries are resolved and im-
mediately prior to database lock.
At the end of the study, essential documentation will
be archived in accordance with sponsor and local re-
quirements. The retention of study data will be the re-
sponsibility of the Chief Investigator. Any data exports
(other than baseline data) will require authorisation by
the trial statistician.
Statistical analysis
The Statistical Analysis Plan will be finalised by the trial
statistician and approved by the TSC and the DMEC prior
to database lock. The study will be unblinded after the
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analysis is planned although pre-defined stopping criteria
will be discussed by the TSC and the Independent DMEC
and agreed if appropriate. Descriptive statistics will be pro-
duced for DMEC reports and in the primary analysis. For
each of the variables analysed, univariate descriptive statis-
tics will be summarised by randomised group to provide
an overview of the data. Summary measures for the base-
line characteristics of each group will be presented as
mean and standard deviation for continuous (approxi-
mate) normally distributed variables, medians and inter-
quartile ranges for non-normally distributed variables, and
frequencies and percentages for categorical variables. The
Area under the Curves (AUC) of the combined symptom
and medication scores for the period corresponding to the
grass pollen season (mid May-Aug) will be plotted against
time as a summary measure of the primary outcome. This
will provide each patient’s longitudinal outcome as a single
quantity, which will be calculated for Symptom and Medi-
cation scores. The planned primary efficacy analysis i.e.
the difference between the two arms in AUC of the
combined symptom and medication scores, will be
analysed on randomised patients using (stratified)
Mann–Whitney U test (Van Elteren test statistic), ad-
justed for the baseline stratification factors (size of the
skin test to grass pollen and presence or absence of
rhinitis symptoms outside the grass pollen season).
Sample size estimation assumed 10% of patients would
not provide evaluable end of study information. If this
rate is observed, multiple imputation methods will be
used in order to provide an overall treatment effect esti-
mate with a standard error that is properly inflated
to incorporate uncertainty associated with imputing
values. Since this may introduce a bias if the main rea-
son for drop-out was deterioration, a sensitivity analysis
will be performed to explore departures from the ‘miss-
ing at random’ assumption. Similar analyses will be
conducted for secondary (symptom scores, medication
scores and individual symptoms) and mechanistic out-
comes. Regression models will be also used to evaluate
the change in RQLQ scores to isolate the effect of the
intervention on each arm after adjusting for stratifica-
tion factors. In analyzing the recovery of the cutaneous
late response at each 3, 6 and 12 month time point, the
size of late response in the group that originally received
active therapy will be compared with the group that ori-
ginally received the control intervention. As a further
sensitivity analysis, all key outcomes will be re-analysed
adjusting for any observed differences at baseline that
are judged to be of clinical importance. Differences be-
tween the groups will be estimated with 95% confidence
intervals. The principal software package will be SAS,
with verification of results from syntax for selected ana-
lyses analysed in STATA.Sample size calculation
Power calculations for the primary outcome (combined
symptom and medication score) were performed based on
raw data from a previous clinical trial of subcutaneous
grass pollen immunotherapy [29]. The power calculation
has been conservatively based on the detection of a clin-
ical effect size 80% of that reported in that trial. Using this
method and a two-sided non-parametric test based on a
Monte Carlo approach, group sample sizes of 35 and 35
achieve 90% power to detect such difference in AUC of
the combined symptom and medication scores at a signifi-
cance level of 0.05. To make allowance for the unknown
distribution of the primary outcome and based on the
lower bound for the asymptotic relative efficiency (ARE)
of the Mann–Whitney U test, we have increased the sam-
ple size by a further 15% to 40 in each arm. Further ac-
counting for a post-randomisation dropout rate of up to
10% consistent with previous trials of grass pollen im-
munotherapy, a total sample size of 90 (45 each arm) is re-
quired. Recruitment will take place several months before
visit 1. At visit 1 randomisation will be performed and the
first injection administered. To ensure that a minimum of
90 participants is randomised, up to 100 screened partici-
pants will be booked for visit 1, allowing for a 10% drop-
out rate between screening and randomisation.
Discussion
This protocol will allow us to test our hypothesis that
low dose intradermal immunotherapy with grass pollen
allergen is an effective treatment in seasonal allergic
rhinitis caused by grass pollen. The first participant was
randomised in February 2013 and the last participant is
expected to complete the trial protocol in August 2014.
Additional files
Additional file 1: Visual Analogue Score. To be completed every
2 weeks over Summer 2013.
Additional file 2: Global evaluation scores: to be completed
September 2013.
Additional file 3: Procedures for Recording and Reporting
Adverse Events.
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